United States · Platforms & data · Finviz

Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance

Published by Finviz · United States 9 h ago

Few biotech earnings reports hinge on a single number the way this one does. Wall Street expects Zymeworks to post roughly $249.7 million in third-quarter revenue when it reports…

Read the full article on Finviz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finviz.com)

Also worth reading

Seeking Alpha

Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance

Share

Also worth reading

MSA Safety beats top-line estimates; reaffirms FY26 outlook

SLB (NYSE:SLB) Stock Breaks Below 50 Day Moving Average After Insider Selling

Australian, Chinese airline stocks jump as oil prices plunge more than 7%

Stock market after midterm elections: What S&P 500 history shows

GraniteShares 3x Short Palantir Daily ETC 3SPA ETF Analysis

S&P 500, Nasdaq Drop As Capex Concerns Grip Tech Investors, Outweighing US-Iran Diplomacy Hope — ORCL, META, PLTR, AAPL In Focus